# Docetaxel

## TAXOTERE inj 80mg/4mL

##### 

| TAH Drug Code      | ITAX8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, head & neck cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | [Breast cancer] Operable (adjuvant treatment): TAC regimen: 75 mg/m2 every 3 weeks for 6 courses in combination with doxorubicin 50mg/m2 and cyclophosphamide 500 mg/m2; Locally advanced or metastatic: 100 mg/m2 every 3 weeks as a single agent; 75 mg/m2 every 3 weeks in combination with doxorubicin 50 mg/m2 as first-line therapy; In combination with weekly trastuzumab: 100 mg/m2 every 3 weeks; In combination with capecitabine: 75 mg/m2 every 3 weeks.  [Non-small cell lung cancer] Chemotherapy-naive patients: 75 mg/m2 every 3 weeks in combination with cisplatin 75 mg/m2 or carboplatin with a target AUC of 6 mg/mL‧min; Patients with prior failure of platinum?based chemotherapy: 75 mg/m2 every 3 weeks as a single agent.  [Prostate cancer] 75 mg/m2 every 3 weeks in combination with oral prednisone or prednisolone 5 mg twice daily. [Gastric adenocarcinoma] 75 mg/m2 every 3 weeks in combination with cisplatin and fluorouracil. [Head and neck cancer] 75 mg/m2 every 3 weeks in combination with cisplatin and fluorouracil for 3 or 4 cycles, followed by radiation therapy. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Severe hypersensitivity to docetaxel or any component of the formulation; severe hypersensitivity to other medications containing polysorbate 80; neutrophil count <1,500/mm3. Canadian labeling: Additional contraindications (not in the US labeling): Severe hepatic impairment; pregnancy; breastfeeding                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | Hematologic reactions especially neutropenia, fever, hypersensitivity reactions, fluid retention, GI disturbances, cutaneous reactions, neurologic symptoms, asthenia, alopecia. Cardiovascular: Edema (47% to 64.1% ), Vasodilatation (27% ) Dermatologic: Alopecia (56.3% to 97.8% ), Disorder of nail (11.4% to 18.5% ), Disorder of skin AND/OR subcutaneous tissue, Nail changes (8.1% to 30.6% ), Pruritus, Rash Gastrointestinal: Diarrhea (32.8% to 42.6% ), Nausea (38.8% to 80.5% ), Stomatitis (41.7% to 69.4% ), Vomiting (22.3% to 44.5% ) Hematologic: Anemia (89.1% to 93.6% ), Leukopenia (95.6% to 98.6% ), Neutropenia (71.4% to 99.5% ) Neurologic: Asthenia (61.8% to 80.8% ), Neuropathy Reproductive: Amenorrhea (61.7% ) Other: Fever of unknown origin (31.2% to 46.5% )                                                                                                                                                                                                                                                                                                                     |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

## Taxotere inj 20mg/1mL

##### 

| TAH Drug Code      | ITAXO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, head & neck cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | [Breast cancer] Operable (adjuvant treatment): TAC regimen: 75 mg/m2 every 3 weeks for 6 courses in combination with doxorubicin 50mg/m2 and cyclophosphamide 500 mg/m2; Locally advanced or metastatic: 100 mg/m2 every 3 weeks as a single agent; 75 mg/m2 every 3 weeks in combination with doxorubicin 50 mg/m2 as first-line therapy; In combination with weekly trastuzumab: 100 mg/m2 every 3 weeks; In combination with capecitabine: 75 mg/m2 every 3 weeks.  [Non-small cell lung cancer] Chemotherapy-naive patients: 75 mg/m2 every 3 weeks in combination with cisplatin 75 mg/m2 or carboplatin with a target AUC of 6 mg/mL‧min; Patients with prior failure of platinum?based chemotherapy: 75 mg/m2 every 3 weeks as a single agent.  [Prostate cancer] 75 mg/m2 every 3 weeks in combination with oral prednisone or prednisolone 5 mg twice daily. [Gastric adenocarcinoma] 75 mg/m2 every 3 weeks in combination with cisplatin and fluorouracil. [Head and neck cancer] 75 mg/m2 every 3 weeks in combination with cisplatin and fluorouracil for 3 or 4 cycles, followed by radiation therapy. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Severe hypersensitivity to docetaxel or any component of the formulation; severe hypersensitivity to other medications containing polysorbate 80; neutrophil count <1,500/mm3. Canadian labeling: Additional contraindications (not in the US labeling): Severe hepatic impairment; pregnancy; breastfeeding                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | Hematologic reactions especially neutropenia, fever, hypersensitivity reactions, fluid retention, GI disturbances, cutaneous reactions, neurologic symptoms, asthenia, alopecia. Cardiovascular: Edema (47% to 64.1% ), Vasodilatation (27% ) Dermatologic: Alopecia (56.3% to 97.8% ), Disorder of nail (11.4% to 18.5% ), Disorder of skin AND/OR subcutaneous tissue, Nail changes (8.1% to 30.6% ), Pruritus, Rash Gastrointestinal: Diarrhea (32.8% to 42.6% ), Nausea (38.8% to 80.5% ), Stomatitis (41.7% to 69.4% ), Vomiting (22.3% to 44.5% ) Hematologic: Anemia (89.1% to 93.6% ), Leukopenia (95.6% to 98.6% ), Neutropenia (71.4% to 99.5% ) Neurologic: Asthenia (61.8% to 80.8% ), Neuropathy Reproductive: Amenorrhea (61.7% ) Other: Fever of unknown origin (31.2% to 46.5% )                                                                                                                                                                                                                                                                                                                     |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

